Nuvation Bio's (NUVB) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Nuvation Bio's stock has received a "sell (D-)" rating from Weiss Ratings, while other analysts have provided mixed assessments, including upgrades to "hold" and "buy" ratings with varying price targets.
• The company's stock recently rose by 10.5%, with its current price at $4.85, and it has a market cap of $1.66 billion.
• Nuvation Bio reported a significant negative net margin of 1,413.43% in its latest earnings, with an EPS of ($0.17), aligning with consensus estimates.

Nuvation Bio (NYSE:NUVB - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

A number of other analysts have also commented on the stock. Wall Street Zen upgraded shares of Nuvation Bio from a "sell" rating to a "hold" rating in a research note on Sunday, August 17th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Nuvation Bio in a research note on Friday, September 19th. Wedbush restated an "outperform" rating and set a $6.00 price target on shares of Nuvation Bio in a research note on Monday, October 13th. Jefferies Financial Group initiated coverage on shares of Nuvation Bio in a research note on Tuesday, September 30th. They set a "buy" rating and a $10.00 price target for the company. Finally, Royal Bank Of Canada raised their price objective on Nuvation Bio from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $7.86.

Nuvation Bio Stock Up 10.5%

Nuvation Bio stock opened at $4.85 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.38 and a current ratio of 9.39. Nuvation Bio has a 52-week low of $1.54 and a 52-week high of $4.87. The firm has a 50 day moving average price of $3.39 and a two-hundred day moving average price of $2.60. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -7.70 and a beta of 1.48.

Nuvation Bio (NYSE:NUVB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). The company had revenue of $4.83 million during the quarter, compared to the consensus estimate of $0.42 million. Nuvation Bio had a negative net margin of 1,413.43% and a negative return on equity of 46.14%. Equities analysts predict that Nuvation Bio will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Nuvation Bio by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company's stock worth $191,000 after purchasing an additional 4,608 shares in the last quarter. Meridian Wealth Management LLC boosted its stake in Nuvation Bio by 5.8% in the second quarter. Meridian Wealth Management LLC now owns 87,115 shares of the company's stock worth $170,000 after buying an additional 4,780 shares in the last quarter. Cresset Asset Management LLC boosted its stake in Nuvation Bio by 3.5% in the second quarter. Cresset Asset Management LLC now owns 143,690 shares of the company's stock worth $280,000 after buying an additional 4,874 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in Nuvation Bio by 20.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 36,486 shares of the company's stock valued at $71,000 after purchasing an additional 6,307 shares during the last quarter. Finally, Pale Fire Capital SE lifted its position in Nuvation Bio by 17.0% in the first quarter. Pale Fire Capital SE now owns 45,642 shares of the company's stock valued at $80,000 after purchasing an additional 6,642 shares during the last quarter. Hedge funds and other institutional investors own 61.67% of the company's stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.